Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells.

Pommier A, Audemard A, Durand A, Lengagne R, Delpoux A, Martin B, Douguet L, Le Campion A, Kato M, Avril MF, Auffray C, Lucas B, Prévost-Blondel A.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13085-90. doi: 10.1073/pnas.1300314110. Epub 2013 Jul 22.

2.

T cells contribute to tumor progression by favoring pro-tumoral properties of intra-tumoral myeloid cells in a mouse model for spontaneous melanoma.

Lengagne R, Pommier A, Caron J, Douguet L, Garcette M, Kato M, Avril MF, Abastado JP, Bercovici N, Lucas B, Prévost-Blondel A.

PLoS One. 2011;6(5):e20235. doi: 10.1371/journal.pone.0020235. Epub 2011 May 25.

3.

Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.

Kimpfler S, Sevko A, Ring S, Falk C, Osen W, Frank K, Kato M, Mahnke K, Schadendorf D, Umansky V.

J Immunol. 2009 Nov 15;183(10):6330-7. doi: 10.4049/jimmunol.0900609. Epub 2009 Oct 19.

4.

Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8+ T cells.

Lengagne R, Le Gal FA, Garcette M, Fiette L, Ave P, Kato M, Briand JP, Massot C, Nakashima I, Rénia L, Guillet JG, Prévost-Blondel A.

Cancer Res. 2004 Feb 15;64(4):1496-501.

5.

Effect of artesunate on immune cells in ret-transgenic mouse melanoma model.

Ramacher M, Umansky V, Efferth T.

Anticancer Drugs. 2009 Nov;20(10):910-7. doi: 10.1097/CAD.0b013e328330caba.

PMID:
19745721
6.

Ret transgenic mouse model of spontaneous skin melanoma: focus on regulatory T cells.

Umansky V, Sevko A.

Pigment Cell Melanoma Res. 2013 Jul;26(4):457-63. doi: 10.1111/pcmr.12104. Epub 2013 Apr 25. Review.

PMID:
23560814
7.

Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.

Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, Borrello I, Kato M, Schadendorf D, Baniyash M, Umansky V.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17111-6. doi: 10.1073/pnas.1108121108. Epub 2011 Oct 3.

8.

Prevention of spontaneous tumor development in a ret transgenic mouse model by ret peptide vaccination with indoleamine 2,3-dioxygenase inhibitor 1-methyl tryptophan.

Zeng J, Cai S, Yi Y, He Y, Wang Z, Jiang G, Li X, Du J.

Cancer Res. 2009 May 1;69(9):3963-70. doi: 10.1158/0008-5472.CAN-08-2476. Epub 2009 Apr 21.

9.

Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma.

Zhao F, Falk C, Osen W, Kato M, Schadendorf D, Umansky V.

Clin Cancer Res. 2009 Jul 1;15(13):4382-90. doi: 10.1158/1078-0432.CCR-09-0399. Epub 2009 Jun 23.

10.

Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.

Sevko A, Sade-Feldman M, Kanterman J, Michels T, Falk CS, Umansky L, Ramacher M, Kato M, Schadendorf D, Baniyash M, Umansky V.

J Invest Dermatol. 2013 Jun;133(6):1610-9. doi: 10.1038/jid.2012.444. Epub 2012 Dec 6.

11.

[Changes of regulatory T cell number in hepatocellular carcinoma-bearing mice and its relationship with tumor growth].

Zhang P, Zhang LN, Zhu FL, Wang Q, Wang XY, Li HY, Liu CM, Gao F, Liu CH.

Zhonghua Zhong Liu Za Zhi. 2007 May;29(5):342-5. Chinese.

PMID:
17892128
12.

Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.

Byrne KT, Zhang P, Steinberg SM, Turk MJ.

J Immunol. 2014 Feb 15;192(4):1433-9. doi: 10.4049/jimmunol.1302139. Epub 2014 Jan 8.

13.

Disrupted lymph node and splenic stroma in mice with induced inflammatory melanomas is associated with impaired recruitment of T and dendritic cells.

Soudja SM, Henri S, Mello M, Chasson L, Mas A, Wehbe M, Auphan-Anezin N, Leserman L, Van den Eynde B, Schmitt-Verhulst AM.

PLoS One. 2011;6(7):e22639. doi: 10.1371/journal.pone.0022639. Epub 2011 Jul 21.

14.

Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation.

Umansky V, Sevko A.

Cancer Immunol Immunother. 2012 Feb;61(2):275-82. doi: 10.1007/s00262-011-1164-6. Epub 2011 Nov 27.

PMID:
22120757
15.

Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.

Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, Umansky V, Cerwenka A.

J Immunol. 2012 Dec 15;189(12):5602-11. doi: 10.4049/jimmunol.1201018. Epub 2012 Nov 14.

16.

Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma.

Alb M, Sie C, Adam C, Chen S, Becker JC, Schrama D.

Cancer Immunol Immunother. 2012 Dec;61(12):2239-49. doi: 10.1007/s00262-012-1290-9. Epub 2012 Jun 7.

17.

Targeting surface nucleolin with a multivalent pseudopeptide delays development of spontaneous melanoma in RET transgenic mice.

El Khoury D, Destouches D, Lengagne R, Krust B, Hamma-Kourbali Y, Garcette M, Niro S, Kato M, Briand JP, Courty J, Hovanessian AG, Prévost-Blondel A.

BMC Cancer. 2010 Jun 24;10:325. doi: 10.1186/1471-2407-10-325.

18.

Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma.

von Felbert V, Córdoba F, Weissenberger J, Vallan C, Kato M, Nakashima I, Braathen LR, Weis J.

Am J Pathol. 2005 Mar;166(3):831-41.

19.

An exhaustion-like phenotype constrains the activity of CD4+ T cells specific for a self and melanoma antigen.

Rausch MP, Hastings KT.

PLoS One. 2015 Apr 15;10(4):e0123332. doi: 10.1371/journal.pone.0123332. eCollection 2015.

20.

Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases.

Lengagne R, Graff-Dubois S, Garcette M, Renia L, Kato M, Guillet JG, Engelhard VH, Avril MF, Abastado JP, Prévost-Blondel A.

J Immunol. 2008 Jan 1;180(1):130-7.

Supplemental Content

Support Center